SE9402370D0 - Use of IGF-I - Google Patents

Use of IGF-I

Info

Publication number
SE9402370D0
SE9402370D0 SE9402370A SE9402370A SE9402370D0 SE 9402370 D0 SE9402370 D0 SE 9402370D0 SE 9402370 A SE9402370 A SE 9402370A SE 9402370 A SE9402370 A SE 9402370A SE 9402370 D0 SE9402370 D0 SE 9402370D0
Authority
SE
Sweden
Prior art keywords
diabetes
subject
high risk
igf
occurrence
Prior art date
Application number
SE9402370A
Other languages
English (en)
Swedish (sv)
Inventor
Charles Thivolet
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9402370A priority Critical patent/SE9402370D0/xx
Publication of SE9402370D0 publication Critical patent/SE9402370D0/xx
Priority to DE69528168T priority patent/DE69528168T2/de
Priority to EP95925202A priority patent/EP0759776B1/de
Priority to PCT/SE1995/000776 priority patent/WO1996001124A1/en
Priority to US08/750,733 priority patent/US6342227B1/en
Priority to AT95925202T priority patent/ATE223729T1/de
Priority to AU29407/95A priority patent/AU689922B2/en
Priority to CA002194403A priority patent/CA2194403A1/en
Priority to JP8503824A priority patent/JPH10502367A/ja
Priority to IL11434395A priority patent/IL114343A0/xx
Priority to US10/050,298 priority patent/US20020132772A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
SE9402370A 1994-07-04 1994-07-04 Use of IGF-I SE9402370D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I
JP8503824A JPH10502367A (ja) 1994-07-04 1995-06-22 糖尿病を予防するためのｉｇｆ−ｉ又はその類似体の使用
US08/750,733 US6342227B1 (en) 1994-07-04 1995-06-22 Use of IGF-I or analogues thereof in the prevention of diabetes
EP95925202A EP0759776B1 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
PCT/SE1995/000776 WO1996001124A1 (en) 1994-07-04 1995-06-22 Use of igf-i or analogues thereof in the prevention of diabetes
DE69528168T DE69528168T2 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
AT95925202T ATE223729T1 (de) 1994-07-04 1995-06-22 Verwendung von igf-i oder entsprechenden analogen in der vorbeugung von diabetes
AU29407/95A AU689922B2 (en) 1994-07-04 1995-06-22 Use of IGF-I or analogues thereof in the prevention of diabetes
CA002194403A CA2194403A1 (en) 1994-07-04 1995-06-22 Use of igf-i or analogues thereof in the prevention of diabetes
IL11434395A IL114343A0 (en) 1994-07-04 1995-06-26 Use of IGF-I in the prevention of diabetes
US10/050,298 US20020132772A1 (en) 1994-07-04 2002-01-16 Use of IGF-I or analogues thereof in the prevention of diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Publications (1)

Publication Number Publication Date
SE9402370D0 true SE9402370D0 (sv) 1994-07-04

Family

ID=20394633

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Country Status (10)

Country Link
US (2) US6342227B1 (de)
EP (1) EP0759776B1 (de)
JP (1) JPH10502367A (de)
AT (1) ATE223729T1 (de)
AU (1) AU689922B2 (de)
CA (1) CA2194403A1 (de)
DE (1) DE69528168T2 (de)
IL (1) IL114343A0 (de)
SE (1) SE9402370D0 (de)
WO (1) WO1996001124A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DE60005806T2 (de) 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
NZ526672A (en) 2001-02-09 2006-10-27 Genentech Inc Process for forming crystalline human insulin-like growth factor-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US20140045923A1 (en) 2009-07-10 2014-02-13 Universidad Autónoma De Barcelona Gene therapy compositions for preventing and/or treating of autoimmune diseases
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123228B1 (de) 1983-04-25 1993-09-29 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1

Also Published As

Publication number Publication date
US6342227B1 (en) 2002-01-29
EP0759776B1 (de) 2002-09-11
WO1996001124A1 (en) 1996-01-18
ATE223729T1 (de) 2002-09-15
EP0759776A1 (de) 1997-03-05
IL114343A0 (en) 1995-10-31
DE69528168T2 (de) 2003-01-09
CA2194403A1 (en) 1996-01-18
JPH10502367A (ja) 1998-03-03
AU2940795A (en) 1996-01-25
DE69528168D1 (de) 2002-10-17
US20020132772A1 (en) 2002-09-19
AU689922B2 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
DE19975031I2 (de) Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.
IT8520271A0 (it) Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
DE69723230D1 (de) Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
NO854182L (no) Feste med flere frihetsgrader.
SE9402370D0 (sv) Use of IGF-I
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
DE3684542D1 (de) Acylcarnitine als absorptionsbeschleuniger fuer die wirkstoffverabreichung ueber die schleimhaeute der nasen-, mund-, sublingual- und vaginalhoehle.
IT1185522B (it) Soluzione oftalmica ad azione antiinfiammatoria
IT7928417A0 (it) Composizioni farmaceutiche con esaltazione dell'attivita'terapeutica di cortisonici.
IT8022925A0 (it) Composizioni di gomma siliconica ad un componente, vulcanizzabili atemperatura ambiente e stabili all'immagazzinamento.
IT8348747A0 (it) Derivati amminometil-benzenici eteroaril-sostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni farmaceutiche che li contengono
ATE13433T1 (de) Peptide als arzneimittel und einige peptide.
DK157303C (da) Daekkende krystalmodifikation af c.i. pigmentroedt 53:1 i beta-fasen, dens fremstilling og anvendelse
NO875479D0 (no) Fremgangsmaate for setting av elektroder i elektrolyseceller.
DE3886371D1 (de) Herstellung des hblv-virus in der hsb-2 zell-linie.
ATE289819T1 (de) Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta- estern desselben
AU1956283A (en) 1-(3-(4-(substited aminomethyl)pyrid-2-yl-oxy)-prop-1-yl- amino) - 2-aminocyclobut-i-ene-3,4-diones
JPS52114322A (en) Photographic lens
DK146785A (da) Pharmaceutisk praeparat med indhold af 9alfa, 11beta-dichlor-16alfa-methyl-21-oxycarbonyldicyclohexylmethyloxypregna-1,4-dien-3,20-dion
IT8621394A0 (it) Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
ROSENTHAL Biological and medical research: Low level radiation, carcinogenesis, toxicology, human protein index, biophysics[Annual Technical Report]
Kim Florence Nightingale & Her Life Value
Hinohara Tracheostomy: Indications and Post-operative Care
JPS5335342A (en) Information memory system